345 related articles for article (PubMed ID: 28526180)
1. Introduction.
Chilton R
Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
[No Abstract] [Full Text] [Related]
2. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
3. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
4. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
Scheen AJ
Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
[No Abstract] [Full Text] [Related]
6. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
7. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Hess DA; Terenzi DC; Trac JZ; Quan A; Mason T; Al-Omran M; Bhatt DL; Dhingra N; Rotstein OD; Leiter LA; Zinman B; Sabongui S; Yan AT; Teoh H; Mazer CD; Connelly KA; Verma S
Cell Metab; 2019 Oct; 30(4):609-613. PubMed ID: 31477497
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
10. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
[TBL] [Abstract][Full Text] [Related]
12. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
13. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
14. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
15. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
[TBL] [Abstract][Full Text] [Related]
16. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME
Langslet G; Zinman B; Wanner C; Hantel S; Espadero RM; Fitchett D; Johansen OE
Diab Vasc Dis Res; 2020; 17(6):1479164120975256. PubMed ID: 33307785
[TBL] [Abstract][Full Text] [Related]
18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
19. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
